N/A N=400 Treatment

Improving Care for Women With Urinary Incontinence (EMPOWER)

Urinary Incontinence

Bottom Line

View on ClinicalTrials.gov: NCT05515198 ↗

Enrolled (actual)

400

Serious AEs

2.5%

Results posted

May 2026

Primary outcome: Primary: Change in Patients' UI Symptoms as Measured by International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) — 8.4; 9.0; 9.9; 8.9 score on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Patient Education (Other); Nurse Navigation (Other); ChatBot (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: Female
Sponsor: University Hospitals Cleveland Medical Center
Primary completion: Dec 2024

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Patients' UI Symptoms as Measured by International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF)	8.4; 9.0; 9.9; 8.9; 7.2; 7.1	—
PRIMARY Patients' UI Symptoms as Measured by International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF)	8.7; 6.5; 8.7	<0.001 sig
SECONDARY Patients' UI Symptoms as Measured by International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF)	8.7; 6.5; 8.7	<0.001 sig
SECONDARY Change in Patients' Perceived Self-efficacy for UI Communication as Measured by the PEPPI	18.2; 18.2; 18.2; 18.8; 20.4; 21.0	—
SECONDARY Patients' Perceived Self-efficacy for UI Communication as Measured by the PEPPI	18.3; 19.9; 23.9	—
SECONDARY Patients' Perceived Self-efficacy for UI Communication as Measured by the PEPPI	18.3; 19.9; 23.9	—
SECONDARY Patient Empowerment as Measured by Number of Participants That Answered Yes to Speaking With Their Provider About UI.	24; 25; 22	—
SECONDARY Change in Overactive Bladder Symptom Severity as Measured by the OABSS	6.2; 6.07; 6.53; 5.4; 4.6; 3.7	—
SECONDARY Overactive Bladder Symptom Severity as Measured by the OABSS	4.4; 4.2; 5.0	—
SECONDARY Overactive Bladder Symptom Severity as Measured by the OABSS	4.4; 4.2; 5.0	—
SECONDARY Change in Urinary Symptoms as Measured by the UDI-6	39; 38; 43; 33; 26; 25	—
SECONDARY Urinary Symptoms as Measured by the UDI-6	26; 24; 32	—
SECONDARY Urinary Symptoms as Measured by the UDI-6	26; 24; 32	—
SECONDARY Change in Impact of UI on Patients' Quality of Life as Measured by the ICIQ-LUTSqol	35; 34; 37; 34; 30; 31	—
SECONDARY Impact of UI on Patients' Quality of Life as Measured by the ICIQ-LUTSqol	35; 29; 33	—
SECONDARY Impact of UI on Patients' Quality of Life as Measured by the ICIQ-LUTSqol	35; 29; 33	—
SECONDARY Change in Patients' Perceived Symptom Improvement as Measured by Number of Participants Who Chose 1-3 on the PGI-I Scale.	1; 10; 5	—
SECONDARY Change in Patients' Perceived Symptom Improvement as Measured by Number of Participants Who Chose 1-3 on the PGI-I Scale.	1; 10; 5	—
SECONDARY Change in Patients' Perceived Symptom Improvement as Measured by Number of Participants Who Chose 1-3 on the PGI-I Scale.	1; 10; 5	—
SECONDARY Number of Practices That Maintain a UI Management Intervention as Measured by the Practice Survey	3; 2; 2	—
SECONDARY Number of Practices That Implement a UI Point Person as Measured by the Practice Survey	2; 0; 2	—

Summary

The overall goal is to improve diagnosis and non-operative management of urinary incontinence in women.

Eligibility Criteria

Inclusion Criteria

Female patient having a primary care provider visit at University Hospitals (UH) Cleveland Primary Care Institute (PCI)
≥ 18 years old
Scores 1 or higher on the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-SF)

Exclusion Criteria

None

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05515198). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.